Diane E. Wilfong's most recent trade in Gilead Sciences, Inc. was a trade of 920 Restricted Stock Unit done . Disclosure was reported to the exchange on June 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | Diane E. Wilfong | Interim Corp Controller & CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 920 | 8,785 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Diane E. Wilfong | Interim Corp Controller & CAO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jun 2025 | 920 | 46,016 (0%) | 0% | - | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | Interim Corp Controller & CAO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.09 per share. | 10 Jun 2025 | 340 | 45,676 (0%) | 0% | 110.1 | 37,431 | Common Stock |
| Impel Pharmaceuticals Inc | Diane E. Wilfong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 13,222 | 13,222 | - | - | Stock Option (right to buy) | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 06 Feb 2023 | 1,864 | 32,575 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 06 Feb 2023 | 1,864 | 11,060 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 06 Feb 2023 | 565 | 32,010 (0%) | 0% | 86.4 | 48,793 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 24 Jan 2023 | 4,100 | 31,955 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 24 Jan 2023 | 1,784 | 27,855 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 24 Jan 2023 | 1,244 | 30,711 (0%) | 0% | 84.0 | 104,521 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Dec 2022 | 318 | 28,651 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Dec 2022 | 318 | 12,924 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Dec 2022 | 149 | 28,502 (0%) | 0% | 88.0 | 13,108 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 09 Nov 2022 | 6,416 | 34,749 (0%) | 0% | 63.9 | 410,047 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 09 Nov 2022 | 6,416 | 10,694 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 09 Nov 2022 | 6,416 | 28,333 (0%) | 0% | 83.5 | 535,736 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 01 Nov 2022 | 16,255 | 44,588 (0%) | 0% | 72.7 | 1,181,739 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 01 Nov 2022 | 16,255 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 01 Nov 2022 | 16,255 | 28,333 (0%) | 0% | 79.3 | 1,288,209 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Sep 2022 | 318 | 28,481 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Sep 2022 | 318 | 13,242 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Sep 2022 | 148 | 28,333 (0%) | 0% | 65.3 | 9,661 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Aug 2022 | 2,479 | 29,229 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Aug 2022 | 2,479 | 13,560 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Aug 2022 | 1,066 | 28,163 (0%) | 0% | 63.1 | 67,307 | Common Stock | |
| Impel Pharmaceuticals Inc | Diane E. Wilfong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 12,789 | 12,789 | - | - | Stock Option (right to buy) | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Jun 2022 | 317 | 26,898 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Jun 2022 | 317 | 16,039 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Jun 2022 | 148 | 26,750 (0%) | 0% | 60.7 | 8,990 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2022 | 18,850 | 18,850 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2022 | 5,610 | 16,356 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2022 | 2,025 | 12,018 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2022 | 2,025 | 26,244 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2022 | 1,272 | 10,746 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2022 | 1,272 | 27,516 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2022 | 935 | 26,581 (0%) | 0% | 57.9 | 54,155 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 06 Feb 2022 | 1,864 | 14,043 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 06 Feb 2022 | 1,864 | 24,739 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 06 Feb 2022 | 520 | 24,219 (0%) | 0% | 63.9 | 33,228 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 17 Aug 2021 | 13,610 | 20,398 (0%) | 0% | 72.5 | 986,725 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 17 Aug 2021 | 9,781 | 5,869 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 17 Aug 2021 | 9,781 | 30,179 (0%) | 0% | 68.8 | 672,444 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 17 Aug 2021 | 3,829 | 34,008 (0%) | 0% | 66.4 | 254,092 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 17 Aug 2021 | 3,829 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Aug 2021 | 2,480 | 15,907 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Aug 2021 | 2,480 | 21,305 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Aug 2021 | 907 | 20,398 (0%) | 0% | 69.2 | 62,801 | Common Stock | |
| Impel Pharmaceuticals Inc | Diane E. Wilfong | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2021 | 11,500 | 11,500 | - | - | Stock Option (right to buy) | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2021 | 17,110 | 17,110 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2021 | 5,085 | 18,387 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2021 | 2,025 | 13,302 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2021 | 2,025 | 19,434 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Mar 2021 | 609 | 18,825 (0%) | 0% | 63.9 | 38,921 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Feb 2021 | 778 | 17,606 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Feb 2021 | 778 | 15,327 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Feb 2021 | 197 | 17,409 (0%) | 0% | 67.3 | 13,256 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 06 Feb 2021 | 1,866 | 17,361 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 06 Feb 2021 | 1,866 | 16,105 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 06 Feb 2021 | 533 | 16,828 (0%) | 0% | 68.5 | 36,489 | Common Stock | |
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 26 Jan 2021 | 1,294 | 15,495 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Nov 2020 | 773 | 18,628 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Nov 2020 | 773 | 14,155 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Nov 2020 | 657 | 14,812 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Nov 2020 | 657 | 17,971 | - | - | Restricted Stock Unit | ||
| Gilead Sciences | Diane E. Wilfong | SVP, Controller & CAO | 10 Nov 2020 | 611 | 14,201 (0%) | 0% | 60.6 | 37,039 | Common Stock |